Compare Stocks: ORMP, DBVT, PHAR, and NVCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$12.35 -1.3%	$13.86	$8.85 ▼ $26.18	$776.54M	-0.95	279,196 shs	137,641 shs
NVCT Nuvectis Pharma	$22.00 +2.9%	$21.40	$5.55 ▼ $29.27	$718.17M	-0.26	185,647 shs	880,110 shs
ORMP Oramed Pharmaceuticals	$4.74 +1.5%	$4.52	$2.09 ▼ $5.47	$197.17M	1.19	198,286 shs	804,634 shs
PHAR Pharming Group	$10.55 -2.1%	$11.71	$9.62 ▼ $21.34	$746.71M	0.01	17,814 shs	7,853 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	0.00%	+4.22%	-13.27%	-20.48%	+26.73%
NVCT Nuvectis Pharma	0.00%	-8.30%	-5.78%	+59.19%	+255.41%
ORMP Oramed Pharmaceuticals	0.00%	+1.72%	-1.04%	+22.16%	+108.81%
PHAR Pharming Group	0.00%	-5.89%	-9.67%	-16.83%	-27.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$12.35 -1.3%	$13.86	$8.85 ▼ $26.18	$776.54M	-0.95	279,196 shs	137,641 shs
NVCT Nuvectis Pharma	$22.00 +2.9%	$21.40	$5.55 ▼ $29.27	$718.17M	-0.26	185,647 shs	880,110 shs
ORMP Oramed Pharmaceuticals	$4.74 +1.5%	$4.52	$2.09 ▼ $5.47	$197.17M	1.19	198,286 shs	804,634 shs
PHAR Pharming Group	$10.55 -2.1%	$11.71	$9.62 ▼ $21.34	$746.71M	0.01	17,814 shs	7,853 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	0.00%	+4.22%	-13.27%	-20.48%	+26.73%
NVCT Nuvectis Pharma	0.00%	-8.30%	-5.78%	+59.19%	+255.41%
ORMP Oramed Pharmaceuticals	0.00%	+1.72%	-1.04%	+22.16%	+108.81%
PHAR Pharming Group	0.00%	-5.89%	-9.67%	-16.83%	-27.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.57	Moderate Buy	$48.50	292.71% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	64.77% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
PHAR Pharming Group	2.20	Hold	$38.67	266.51% Upside

Current Analyst Ratings Breakdown

Latest ORMP, DBVT, PHAR, and NVCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/8/2026	ORMP Oramed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
9/4/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	NVCT Nuvectis Pharma	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$40.00
9/1/2026	NVCT Nuvectis Pharma	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	NVCT Nuvectis Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/20/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/5/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$5.64M	137.69	N/A	N/A	$4.20 per share	2.94
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
ORMP Oramed Pharmaceuticals	$2M	98.59	$0.09 per share	52.25	$5.02 per share	0.94
PHAR Pharming Group	$376.13M	1.99	$0.20 per share	52.61	$3.95 per share	2.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	1.15	N/A	N/A	N/A	-5.17%	-4.54%	11/12/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	87.92	42.20	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)

Latest ORMP, DBVT, PHAR, and NVCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.09	-$0.52	$1.84	N/A	N/A
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	5.27%	N/A	6.07%	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	3.72	3.72
NVCT Nuvectis Pharma	N/A	1.68	1.68
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98
PHAR Pharming Group	0.34	3.01	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
NVCT Nuvectis Pharma	96.77%
ORMP Oramed Pharmaceuticals	12.73%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.06%
NVCT Nuvectis Pharma	28.55%
ORMP Oramed Pharmaceuticals	20.77%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
ORMP Oramed Pharmaceuticals	13	41.60 million	32.96 million	Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable

ORMP, DBVT, PHAR, and NVCT Headlines

Recent News About These Companies

FY2027 EPS Estimates for Pharming Group Cut by HC Wainwright

September 18 at 1:28 AM | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) versus Pharming Group (NASDAQ:PHAR) Financial Comparison

September 17 at 3:16 AM | americanbankingnews.com

FY2026 EPS Estimates for Pharming Group Cut by HC Wainwright

September 17 at 1:15 AM | americanbankingnews.com

Pharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness?

September 16, 2026 | insidermonkey.com

Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - What's Next?

September 16, 2026 | marketbeat.com

FY2027 EPS Forecast for Pharming Group Lowered by Analyst

September 16, 2026 | marketbeat.com

HC Wainwright Reiterates Buy Rating for Pharming Group (NASDAQ:PHAR)

September 16, 2026 | americanbankingnews.com

FY2026 EPS Forecast for Pharming Group Decreased by Analyst

September 15, 2026 | marketbeat.com

Pharming Group N.V. (PHAR) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow

September 14, 2026 | seekingalpha.com

Pharming Group's (PHAR) "Buy" Rating Reiterated at HC Wainwright

September 14, 2026 | marketbeat.com

Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja

September 14, 2026 | marketscreener.comM

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

September 12, 2026 | marketbeat.com

Pharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11

September 11, 2026 | marketscreener.comM

Pharming Gets FDA Approval For Joenja In Children With APDS

September 11, 2026 | rttnews.com

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

September 11, 2026 | finance.yahoo.com

FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.

September 11, 2026 | globenewswire.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Time to Sell?

September 10, 2026 | marketbeat.com

Pharming: Faltering Rare-Disease Franchise With Two Potentially Transformative Late-Stage Assets

September 9, 2026 | seekingalpha.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Recommendation of "Hold" by Brokerages

September 7, 2026 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Should You Buy?

September 2, 2026 | marketbeat.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Increase in Short Interest

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ORMP, DBVT, PHAR, and NVCT Company Descriptions

DBV Technologies NASDAQ:DBVT

$12.35 -0.16 (-1.28%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.35 0.00 (0.00%)

As of 09/18/2026 04:10 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Nuvectis Pharma NASDAQ:NVCT

$22.00 +0.62 (+2.90%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$22.15 +0.15 (+0.66%)

As of 09/18/2026 07:44 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Oramed Pharmaceuticals NASDAQ:ORMP

$4.74 +0.07 (+1.50%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.69 -0.05 (-1.14%)

As of 09/18/2026 07:50 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Pharming Group NASDAQ:PHAR

$10.55 -0.23 (-2.13%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.60 +0.05 (+0.47%)

As of 09/18/2026 04:10 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, DBVT, PHAR, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, DBVT, PHAR, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, DBVT, PHAR, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ORMP, DBVT, PHAR, and NVCT Company Descriptions

DBV Technologies NASDAQ:DBVT

Nuvectis Pharma NASDAQ:NVCT

Oramed Pharmaceuticals NASDAQ:ORMP

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, DBVT, PHAR, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, DBVT, PHAR, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, DBVT, PHAR, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ORMP, DBVT, PHAR, and NVCT Company Descriptions

DBV Technologies NASDAQ:DBVT

Nuvectis Pharma NASDAQ:NVCT

Oramed Pharmaceuticals NASDAQ:ORMP

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools